Bridge doses first patient in Phase lla trial of IPF therapy

Bridge doses first patient in Phase lla trial of IPF therapy

Source: 
Clinical Trials Arena
snippet: 

South Korean biotech firm Bridge Biotherapeutics has dosed the first patient in its Phase lla trial of BBT-877 to treat patients with idiopathic pulmonary fibrosis (IPF).